Every material Form 8-K DaVita filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
DaVita reported third-quarter 2024 results. Revenue rose to $3.264 billion from $3.121 billion a year earlier and operating income rose to $535 million, but diluted EPS fell to $2.50 from $2.62 and net income attributable to DaVita fell to $215 million from $247 million. The company kept its 2024 adjusted guidance, which now includes center closure costs, and reported $406 million of share repurchases in the quarter.
Total revenues were $3.264 billion for the quarter ended September 30, 2024, versus $3.121 billion in the same quarter of 2023.
Diluted EPS was $2.50 versus $2.62 a year earlier; adjusted diluted EPS was $2.59.
2024 guidance: adjusted operating income of $1.91 billion to $2.01 billion, adjusted diluted EPS of $9.25 to $10.05, and free cash flow of $950 million to $1.2 billion.
The company repurchased 2.7 million shares for $406 million in the third quarter.
DaVita appointed Senior Vice President David P. Maughan as Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024, replacing Michael D. Staffieri, who moves to Chief Operating Officer Emeritus. The company also entered an employment agreement with Maughan with a $725,000 base salary and a 2024 target bonus of 100% of base salary.
David P. Maughan, 47, succeeds Michael D. Staffieri as COO, DaVita Kidney Care, effective September 15, 2024
Maughan joined DaVita in 2006 and most recently served as Senior Vice President, Kidney Care, from November 2019 to September 2024
Employment agreement sets annual base salary of $725,000 and a 2024 target incentive bonus equal to 100% of base salary
Severance includes at least one year of base salary continuation on resignation for good cause, or two years within 60 days after a good-cause event following a change in control
DaVita completed a $1.0 billion private offering of 6.875% senior notes due 2032 on August 13, 2024, and entered into a credit agreement amendment adding a $1.1 billion incremental term loan maturing April 28, 2028. The company said net proceeds of about $2,080.7 million were used to repay roughly $950.0 million of Tranche B-1 term loans and $60.0 million of revolving loans, with $350.0 million more of revolving loans planned for repayment. The refinancing changes the company's debt mix and interest costs, but the filing does not state the effect on total debt.
$1.0 billion of 6.875% senior notes due September 1, 2032, issued in a private offering completed August 13, 2024
$1.1 billion incremental Term Loan A-1 facility maturing April 28, 2028, with quarterly amortization starting September 30, 2024
Net proceeds of about $2,080.7 million used to repay roughly $950.0 million of 2026 term loans and $60.0 million of revolving loans
Remaining proceeds planned for $350.0 million of revolving loan repayment and general corporate purposes, including possible share repurchases
DaVita reported second-quarter 2024 revenue of $3.187 billion, up from $3.000 billion a year earlier, and diluted EPS of $2.50 versus $1.91. The company raised its 2024 adjusted diluted EPS guidance to $9.25-$10.05 from $9.00-$9.80, though the filing notes that the change reflects a new presentation that no longer excludes about $60 million in center closure costs.
Q2 2024 total revenues were $3.187 billion versus $3.000 billion in Q2 2023; operating income was $506 million versus $405 million.
Diluted EPS was $2.50 versus $1.91 a year earlier; adjusted diluted EPS was $2.59 versus $2.26 in the first quarter of 2024.
Current 2024 adjusted diluted EPS guidance is $9.25 to $10.05, compared with prior guidance of $9.00 to $9.80 given as of May 2, 2024.
During Q2 2024 the company repurchased 2.7 million shares for $376 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DaVita filing is on SEC EDGAR ↗. 8-K briefs of other companies →